• Je něco špatně v tomto záznamu ?

Comprehensive Evaluation of the Ability of Comorbidity and Health Status Indices to Improve the Prediction of Perioperative Morbidity and Long-Term Survival Outcomes After Radical Cystectomy

M. von Deimling, M. Rink, J. Klemm, M. Koelker, V. Schuettfort, F. König, P. Gild, TA. Ludwig, P. Marks, R. Dahlem, M. Fisch, SF. Shariat, MW. Vetterlein

. 2024 ; 22 (2) : 336-346.e9. [pub] 20231207

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24006590

BACKGROUND: In the era of standardized outcome reporting, it remains unclear if widely used comorbidity and health status indices can enhance predictive accuracy for morbidity and long-term survival outcomes after radical cystectomy (RC). PATIENTS AND METHODS: In this monocentric study, we included 468 patients undergoing open RC with pelvic lymph node dissection for bladder cancer between January 2009 and December 2017. Postoperative complications were meticulously assessed according to the EAU guideline criteria for standardized outcome reporting. Multivariable regression models were fitted to evaluate the ability of ASA physical status (ASA PS), Charlson comorbidity index (± age-adjustment) and the combination of both to improve prediction of (A) 30-day morbidity key estimates (major complications, readmission, and cumulative morbidity as measured by the Comprehensive Complication index [CCI]) and (B) secondary mortality endpoints (overall [OM], cancer-specific [CSM], and other-cause mortality [OCM]). RESULTS: Overall, 465 (99%) and 52 (11%) patients experienced 30-day complications and major complications (Clavien-Dindo grade ≥IIIb), respectively. Thirty-seven (7.9%) were readmitted within 30 days after discharge. Comorbidity and health status indices did not improve the predictive accuracy for 30-day major complications and 30-day readmission of a reference model but were associated with 30-day CCI (all P < .05). When ASA PS and age-adjusted Charlson index were combined, ASA PS was no longer associated with 30-day CCI (P = .1). At a median follow-up of 56 months (IQR 37-86), OM, CSM, and 90-day mortality were 37%, 24%, and 2.9%, respectively. Both Charlson and age-adjusted Charlson index accurately predicted OCM (all P < .001) and OM (all P ≤ .002) but not CSM (all P ≥ .4) and 90-day mortality (all P > .05). ASA PS was not associated with oncologic outcomes (all P ≥ .05). CONCLUSION: While comorbidity and health status indices have a role in predicting OCM and OM after RC, their importance in predicting postoperative morbidity is limited. Especially ASA PS performed poorly. This highlights the need for procedure-specific comorbidity assessment rather than generic indices.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24006590
003      
CZ-PrNML
005      
20240423155357.0
007      
ta
008      
240412s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.clgc.2023.12.002 $2 doi
035    __
$a (PubMed)38199879
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a von Deimling, Markus $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Electronic address: m.von-deimling@uke.de
245    10
$a Comprehensive Evaluation of the Ability of Comorbidity and Health Status Indices to Improve the Prediction of Perioperative Morbidity and Long-Term Survival Outcomes After Radical Cystectomy / $c M. von Deimling, M. Rink, J. Klemm, M. Koelker, V. Schuettfort, F. König, P. Gild, TA. Ludwig, P. Marks, R. Dahlem, M. Fisch, SF. Shariat, MW. Vetterlein
520    9_
$a BACKGROUND: In the era of standardized outcome reporting, it remains unclear if widely used comorbidity and health status indices can enhance predictive accuracy for morbidity and long-term survival outcomes after radical cystectomy (RC). PATIENTS AND METHODS: In this monocentric study, we included 468 patients undergoing open RC with pelvic lymph node dissection for bladder cancer between January 2009 and December 2017. Postoperative complications were meticulously assessed according to the EAU guideline criteria for standardized outcome reporting. Multivariable regression models were fitted to evaluate the ability of ASA physical status (ASA PS), Charlson comorbidity index (± age-adjustment) and the combination of both to improve prediction of (A) 30-day morbidity key estimates (major complications, readmission, and cumulative morbidity as measured by the Comprehensive Complication index [CCI]) and (B) secondary mortality endpoints (overall [OM], cancer-specific [CSM], and other-cause mortality [OCM]). RESULTS: Overall, 465 (99%) and 52 (11%) patients experienced 30-day complications and major complications (Clavien-Dindo grade ≥IIIb), respectively. Thirty-seven (7.9%) were readmitted within 30 days after discharge. Comorbidity and health status indices did not improve the predictive accuracy for 30-day major complications and 30-day readmission of a reference model but were associated with 30-day CCI (all P < .05). When ASA PS and age-adjusted Charlson index were combined, ASA PS was no longer associated with 30-day CCI (P = .1). At a median follow-up of 56 months (IQR 37-86), OM, CSM, and 90-day mortality were 37%, 24%, and 2.9%, respectively. Both Charlson and age-adjusted Charlson index accurately predicted OCM (all P < .001) and OM (all P ≤ .002) but not CSM (all P ≥ .4) and 90-day mortality (all P > .05). ASA PS was not associated with oncologic outcomes (all P ≥ .05). CONCLUSION: While comorbidity and health status indices have a role in predicting OCM and OM after RC, their importance in predicting postoperative morbidity is limited. Especially ASA PS performed poorly. This highlights the need for procedure-specific comorbidity assessment rather than generic indices.
650    _2
$a lidé $7 D006801
650    12
$a cystektomie $x škodlivé účinky $7 D015653
650    _2
$a retrospektivní studie $7 D012189
650    12
$a nádory močového měchýře $x patologie $7 D001749
650    _2
$a komorbidita $7 D015897
650    _2
$a morbidita $7 D009017
650    _2
$a ukazatele zdravotního stavu $7 D006305
650    _2
$a pooperační komplikace $x etiologie $7 D011183
655    _2
$a časopisecké články $7 D016428
700    1_
$a Rink, Michael $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Klemm, Jakob $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Koelker, Mara $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Schuettfort, Victor $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a König, Frederik $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Gild, Philipp $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Ludwig, Tim A $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Marks, Phillip $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Dahlem, Roland $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Fisch, Margit $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Department of Urology, Weill Cornell Medical College, New York, NY; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria
700    1_
$a Vetterlein, Malte W $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
773    0_
$w MED00188741 $t Clinical genitourinary cancer $x 1938-0682 $g Roč. 22, č. 2 (2024), s. 336-346.e9
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38199879 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155353 $b ABA008
999    __
$a ok $b bmc $g 2080909 $s 1216357
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 22 $c 2 $d 336-346.e9 $e 20231207 $i 1938-0682 $m Clinical genitourinary cancer $n Clin Genitourin Cancer $x MED00188741
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace